Patented small molecule inhibitors in the ubiquitin proteasome system

被引:60
作者
Guedat, Philippe [1 ]
Colland, Frederic [1 ]
机构
[1] Hybrigenics SA, F-75014 Paris, France
来源
BMC BIOCHEMISTRY | 2007年 / 8卷
关键词
D O I
10.1186/1471-2091-8-S1-S14
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Deregulation of the ubiquitin proteasome system (UPS) has been implicated in the pathogenesis of many human diseases, including cancer and neurodegenerative disorders. The recent approval of the proteasome inhibitor Velcade (R) (bortezomib) for the treatment of multiple myeloma and mantle cell lymphoma establishes this system as a valid target for cancer treatment. We review here new patented proteasome inhibitors and patented small molecule inhibitors targeting more specific UPS components, such as E3 ubiquitin ligases and deubiquitylating enzymes.
引用
收藏
页数:12
相关论文
共 118 条
[1]  
3 DIMENSIONAL PHARM, 2003, Patent No. 03095625
[2]  
3 DIMENSIONAL PHARM, 2004, Patent No. 2004096134
[3]  
Adams J, 1999, CANCER RES, V59, P2615
[4]   The proteasome: A suitable antineoplastic target [J].
Adams, J .
NATURE REVIEWS CANCER, 2004, 4 (05) :349-360
[5]  
ALCON INC, 2002, Patent No. 0294311
[6]   The trans-Golgi network-associated human ubiquitin-protein ligase POSH is essential for HIV Woe 1 production [J].
Alroy, I ;
Tuvia, S ;
Greener, T ;
Gordon, D ;
Barr, HM ;
Taglicht, D ;
Mandil-Levin, R ;
Ben-Avraham, D ;
Konforty, D ;
Nir, L ;
Levius, O ;
Bicoviski, V ;
Dori, M ;
Cohen, S ;
Yaar, L ;
Erez, O ;
Propheta-Meiran, O ;
Koskas, M ;
Caspi-Bachar, E ;
Alchanati, I ;
Sela-Brown, A ;
Moskowitz, H ;
Tessmer, U ;
Schubert, U ;
Reiss, Y .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (05) :1478-1483
[7]  
ALS THERAPY DEV FDN, 2003, Patent No. 03101481
[8]  
APREA AB, 2004, Patent No. 2004035580
[9]  
AXYS PHARM, 2004, Patent No. 2004014882
[10]  
Bacon K., 2004, Substituted heterocycles, Patent No. [071, 382, 2004071382, WO2004071382]